The personalization of cancer treatment is evolving rapidly. Developing a personalized cancer vaccine is a promising strategy for cancer treatment.
Body cells constantly present peptides on their surface, indicating the current state of the cell. Immune cells can recognize if a cell presents normal or abnormal peptides and use this information to determine and eliminate defective cells. Abnormal peptides, so-called neoantigens, arise from DNA mutations in tumor cells and are targets for therapy using personalized vaccines.
CeGaT CancerNeo® enables the analysis of a patient’s tumor exome to detect tumor-specific (somatic) mutations, identifies the HLA-types, and predicts neoantigens. The expression of these neoantigens is confirmed by whole RNA sequencing (transcriptome) from the same tumor sample. Thus, CeGaT’s CancerNeo® provides the insights required for the design of personalized cancer vaccines – a powerful tool to boost the immune system’s response to cancer cells.
Are you insured in Germany? Our colleagues at the Zentrum für Humangenetik Tübingen will gladly support you!